Novo Nordisk CEO Puts Pricing On The Line
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.
You may also be interested in...
New insulin-cartridge holders are being sent to users worldwide after the use of cleaning chemicals was linked to cracked holders in specific batches of NovoPen Echo and NovoPen 5, and increased ADR risks.
As Sanofi joined the ranks of pharma companies pledging to limit annual US price increases, the company also released average aggregate list and net prices in 2016, showing net prices declined 2.1%.
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.